Montelukast versus inhaled corticosteroids as monotherapy for prevention of asthma: which one is best?

Stefano Miceli Sopo, Roberta Onesimo, D. Radzik, G. Scala, F. Cardinale

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

The GINA guidelines (GL)1, the BTS-SIGN GL2, and the paediatric PRACTALL GL3, indicate inhaled corticosteroids (ICS) as the frst choice for controller therapy of paediatric asthma. The authors of BTS-SIGN GL recommended a leukotriene receptor antagonist, if ICS cannot be administered. Montelukast (MLK) is the most commonly used in children. If ICS remain the frst choice, they can be considered the Gold Standard for pharmacological asthma prevention and the value of any alternative treatment must be measured against them, not only against a placebo. Here we will try to shed some light as to which of those two drugs is better according to the present evidence.
Original languageEnglish
Pages (from-to)26-30
Number of pages5
JournalAllergologia et Immunopathologia
Volume2009
Publication statusPublished - 2009

Keywords

  • asthma

Fingerprint Dive into the research topics of 'Montelukast versus inhaled corticosteroids as monotherapy for prevention of asthma: which one is best?'. Together they form a unique fingerprint.

Cite this